Qiagen (NYSE:QGEN) Issues FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.430- for the period, compared to the consensus estimate of 2.430. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on QGEN shares. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Monday, May 18th. Zacks Research raised shares of Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $43.00 target price on shares of Qiagen in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $43.34.

Qiagen Stock Performance

NYSE QGEN traded down $0.40 during trading hours on Wednesday, hitting $41.93. The company’s stock had a trading volume of 2,037,433 shares, compared to its average volume of 2,431,492. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The company’s 50 day simple moving average is $39.10 and its two-hundred day simple moving average is $41.77. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. The company has a market cap of $8.64 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 4.22 and a beta of 0.63.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.54. The company had revenue of $492.32 million for the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same quarter last year, the company posted $0.56 earnings per share. As a group, sell-side analysts expect that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. Qiagen’s dividend payout ratio is currently 18.32%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Danske Bank A S purchased a new stake in Qiagen in the 3rd quarter worth approximately $36,000. Global Retirement Partners LLC lifted its holdings in Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Qiagen in the third quarter worth approximately $64,000. Kestra Advisory Services LLC bought a new position in shares of Qiagen in the fourth quarter worth approximately $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Qiagen in the fourth quarter worth $73,000. Institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.